While the MYLK rs3732487 and rs3732486 variants showed similar patterns of increased risk of benign breast tumors (OR = 1.20, 95% CI: 1.09–1.32, p = 1.94 × 10−4; OR = 1.19, 95% CI: 1.08–1.31, p = 3.52 × 10−4, respectively) and osteoporosis (OR = 1.21, 95% CI: 1.09–1.35, p = 2.57 × 10−4; OR = 1.21, 95% CI: 1.09–1.34, p = 3.23 × 10−4, respectively), the rs12163585 variant was associated with a decreased risk of benign breast tumors and osteoporosis (OR = 0.87, 95% CI: 0.79–0.96, p = 5.69 × 10−3; OR = 0.88, 95% CI: 0.80–0.98, p = 1.98 × 10−2, respectively) (Table 3). This evidence concerns the gene MYLK and breast benign neoplasm.